How to Detect Converted THC: Solvent Fingerprints, Isomer Signatures, and the Colorado Methylene Chloride Recall

A converted THC product leaves three kinds of evidence: a solvent that no extraction process uses, an isomer profile the plant does not make, and a catalyst residue the standard panels never look for. Methylene chloride at any level above the 600 ppm USP Class 2 limit, delta-8 THC above 1 percent, delta-10 or iso-THC at any level, or a non-detect delta-9 result on a product sold as THC each point to a converted or semi-synthetic product rather than a botanical extract. The Colorado StayCon recall of September 2026 is the working example: 49 vape products, sold at 405 stores for up to 18 months, were pulled after a third-party lab found methylene chloride during a routine pesticide and mold screen. The solvent was never on the residual solvent panel the state requires, which is exactly why it went unnoticed for a year and a half. The incoming-ingredient control that stops a solvent-contaminated terpene lot at the receiving dock is in our terpene supplier COA guide.

This guide is written for the people who have to make the call: QA leads releasing product, labs choosing what to run, regulators reading a COA, and buyers deciding whether a distillate lot is what the paperwork says. It covers the routes converters actually use, the residues each route leaves, the thresholds that separate a botanical extract from a converted one, and the failures that let converted oil through a compliant testing program.

What Conversion Is and Why It Shows Up in Regulated Markets

Conversion means taking cannabidiol, usually as hemp-derived CBD isolate at 99 percent purity, and closing its open ring with an acid catalyst so it rearranges into a tetrahydrocannabinol. Depending on the catalyst and conditions the product is mostly delta-9 THC, mostly delta-8 THC, or a mix, along with byproducts the plant never produces. The chemistry is covered route by route in the acid catalyst comparison and its failure modes in the isomerization troubleshooting guide. The economics are the reason it appears inside licensed markets: hemp CBD isolate trades for a small fraction of the price of licensed THC distillate, so a converted kilogram sold as botanical distillate carries a margin no honest extraction can match. When a converted oil is filled into carts and labeled as state-licensed cannabis, the practice is called inversion, and Colorado, like most licensed states, prohibits both the conversion process and the solvent the recall exposed.

What Is Conversion Oil?

Conversion oil is THC distillate made by isomerizing hemp CBD isolate with an acid catalyst instead of extracting it from THC-dominant cannabis. A typical lot runs 70 to 95 percent total THC, carries 1 to 15 percent delta-8 in a product labeled delta-9, shows percent-level unreacted CBD, has none of the minor cannabinoids a plant extract carries (CBG, CBC, THCV, CBN at 0.1 to 3 percent each in botanical distillate), and brings the catalyst and workup solvent along with it. It is sold three ways: openly as hemp-derived delta-9 or delta-8, quietly as inverted material filled into state-licensed cartridges, and increasingly inside blends whose certificates list only the carrier. Under Section 781 of Public Law 119-37 every cannabinoid the plant cannot naturally produce loses hemp status on November 12, 2026; converted delta-8 and delta-9 are cannabinoids the plant also makes, so conversion oil follows on December 11, 2026 under the exclusion for cannabinoids synthesized outside the plant; our hemp ban breakdown covers the two dates.

The table below is the release-desk version of this whole guide: what a botanical distillate looks like on each line of a certificate, what conversion oil looks like on the same line, and the test that shows the difference. Every row below it is explained in the sections that follow.

Read the last row twice, because it is the one most summaries get wrong. A chiral column separates enantiomers. Converted THC made from plant CBD is the same enantiomer as plant THC, so chirality tells you nothing about CBD conversion. It flags a different product: THC built from olivetol and a racemic terpene, which is a total synthesis and a different detection problem. For CBD-derived conversion the evidence is the isomer set, the missing minors, and the solvent, in that order.

Evidence Type 1: The Solvent Fingerprint

Extraction uses a short list of solvents: butane, propane, ethanol, carbon dioxide, and occasionally heptane, pentane, or isopropanol for post-processing. Conversion uses a different list, because a Lewis or Bronsted acid reaction and its workup need a solvent that dissolves the catalyst, tolerates the acid, and separates cleanly from water. Methylene chloride (dichloromethane), toluene, hexane, and chloroform are the working solvents of conversion, and none of them has any place in a legal extraction lab. Finding one is not a purge failure. It is a route disclosure.

The catalyst loadings, temperatures, and conversion figures in that table are the same ones a converter works from; they are published in the acid catalyst comparison. Read them from the other side and they become a detection key.

Residual solvent limits that matter for detection

USP General Chapter 467 sorts solvents into three classes by toxicity, and most state cannabis panels borrow the numbers even when they do not borrow the full list. Class 1 solvents are to be avoided entirely, Class 2 are limited by a permitted daily exposure, and Class 3 are considered low risk with a 5,000 ppm ceiling.

Two things follow from the table. A residual solvent panel that copies only the hydrocarbon and ethanol lines will never see a conversion solvent, and a lab that runs the full USP list on a headspace GC sees it in the same injection at no extra cost. The state’s list is a floor. Release testing that stops at the floor is how a converted cart sits on 405 shelves for 18 months.

Evidence Type 2: The Isomer Signature

Cannabis biosynthesis makes THCA, and decarboxylation makes delta-9 THC from it. The plant does not make delta-10 THC, it does not make the iso-THC isomers, and it makes delta-8 only as a trace oxidation and isomerization product, well under 1 percent of total cannabinoids in fresh flower and rarely much above it even in aged distillate. Acid catalysis is not that selective. Every conversion route produces a spread of isomers because the same carbocation intermediate can close and lose a proton in several positions, and a converter cannot fully remove them without the chromatography step that would erase the cost advantage. The acid-side version of the question, whether a THCA lot grew in a trichome or came out of a carboxylation step, is covered in CBDA to THCA Conversion: What a Lab Can Prove.

Chirality adds one more layer for a lab that wants it. Plant THC is essentially all the (6aR,10aR) trans enantiomer. Conversion from CBD preserves those two stereocenters, so enantiomeric purity does not by itself separate converted delta-9 from botanical delta-9; what it does catch is the cis-THC that appears in some acid-catalyzed products and never in flower. Treat chiral analysis as confirmation on a flagged sample, not as a screen.

Evidence Type 3: What the Panels Do Not Run

Most state programs require potency, residual solvents from a fixed list, pesticides, microbials, mycotoxins, and four heavy metals. That program was designed to catch a bad extraction, not a different synthesis. Boron from BF3 is not screened anywhere. Zinc is not on the four-metal panel. Delta-10 and the iso-THC isomers are not required analytes, so a lab that does not stock the standards reports them as nothing. A converted product can therefore pass a compliant panel on every line while carrying three or four independent tells, and it will keep passing until someone runs the one test that is not required. In Colorado that test turned out to be a pesticide screen whose method happened to see methylene chloride.

Masked and Acetylated THC: Why the Potency Panel Reads Non-Detect

A potency panel reports what the lab holds a reference standard for, and nothing else. California’s rule names the example panel as THC, THCA, CBD, CBDA, CBG, and CBN (4 CCR 15724), and nothing on it is an acetate. A cart filled with delta-8 THC-O acetate, HHC, or THCP can come back with delta-9 at non-detect and a total that looks like a typo, because the active ingredient eluted as an unnamed peak or was never integrated. A non-detect from a method that was never calibrated for the compound is a blank, not a result.

The same blind spot breaks the isomers the panel does claim to measure. Washington’s cannabis board heard it from KCA Labs in 2023: reversed-phase HPLC-UV is not fit for purpose on CBD-derived delta-8, because delta-8-iso-THC co-elutes with delta-8 and delta-4(8)-iso-THC lands beside delta-9 with an identical formula and UV spectrum. GC-MS resolves all four. When Ray and colleagues ran ten delta-8 products by NMR in 2022, the impurity signals came to 11.7 to more than 17 percent of the main peak, on products whose certificates claimed 93 to 99 percent purity or better.

The instrument choice cuts both ways. Potency runs on HPLC because a hot GC inlet decarboxylates THCA only partway: Dussy and colleagues measured a maximum of about 67 to 70 percent conversion at a 220°C injector, so a GC total THC undercounts acid-rich material. Acetates behave the opposite way. Evans and colleagues (Analyst, 2026) saw no thermal breakdown of delta-8 THC-O to delta-8 THC in a 290°C splitless inlet, which makes GC-MS the right confirmation tool for acetates even though it is the wrong tool for acid potency. The bottleneck is the standard: when Holt, Poklis, and Peace reported the first THC-O acetates in commercial products in 2022, no certified standard existed, and they synthesized their own from delta-8, delta-9, and delta-10 THC with acetic anhydride.

The residues that name the route

The best published residue survey is Meehan-Atrash and Rahman (Chemical Research in Toxicology, 2022): 27 delta-8 vape products from 10 brands, run by NMR, GC-MS, and ICP-MS. None carried an accurate delta-8 label and 11 held unlabeled cutting agents. What each residue tells you about how the oil was made is below; the chemistry of how each one forms is in our isomerization byproducts guide, and the synthesis routes for HHC and THCP are in novel cannabinoid synthesis from CBD.

Read the last row carefully. A metals result is not route proof on its own; the isomer spread is the primary screen and metals only support it.

Why an acetate fails in a cart whatever the label says

Masking is a compliance problem until the cart is fired, and then it is an exposure problem. Munger, Jensen, and Strongin showed in 2022 that vaping THC, CBN, and CBD acetates produces ketene, the same reactive gas tied to vitamin E acetate vaping (Wu and O’Shea, PNAS 2020). Evans and colleagues put numbers on it in 2026 with a commercial ceramic-coil vape: the acetyl group left as ketene at more than 99 percent efficiency, ketene came to 1 to 4 percent of the cannabinoid mass, delta-8 THC-O gave 1.4 plus or minus 0.5 percent, and CBD-di-O gave 3.1 times that. The plain cannabinoids under the same conditions made no ketene at all. Only 1.2 percent of the delta-8 THC-O reverted to delta-8 THC, so the user is not even getting the THC the acetate was supposed to deliver. What heat does to THC itself, temperature by temperature, is in what happens to THC when heated.

Section 781 of Public Law 119-37 removes from the federal hemp definition any cannabinoid “synthesized or manufactured outside the plant.” An acetate is made outside the plant by definition, so an acetate screen stops being a curiosity and becomes the evidence that decides which side of that line a product sits on. For a release program, the fix is one line: any lot with an unidentified peak above 0.5 percent of area goes to GC-MS before it ships, and any lot sold as delta-9 with delta-9 at non-detect is presumed masked until a lab names what is in it.

The Colorado StayCon Recall as a Case Study

The timeline matters more than the headline. In August 2026, Denver-based Bona Fides Laboratory detected methylene chloride in StayCon vape oil during routine pesticide and mold screening, and its owner notified the manufacturer and the state Marijuana Enforcement Division. Roughly six weeks later StayCon voluntarily recalled 49 vape products sold under the Maui Wowie and Grape Gorilla names, some of which had been on shelves at more than 400 stores for over 18 months. The company’s recall notice attributed the solvent to a botanically derived flavoring compound. The state had not issued its own advisory at the time of the recall, and its investigation was described as ongoing. A licensed cultivator had supplied regulators with 2024 third-party results indicating a StayCon vape was made from chemically synthesized hemp material; the state said its own tests found no synthetically derived THC and took no action at the time.

Read against the two tables above, the recall reads as a route disclosure rather than a contamination accident. Methylene chloride is a Class 2 solvent with no role in flavoring, extraction, or formulation; it is the workup solvent for the Lewis acid and mineral acid conversion routes. Whether the solvent arrived in a purchased input or in the manufacturer’s own reactor is a question the release testing should have answered before the first cart shipped, and a full USP 467 headspace run would have answered it in one injection.

Common Failures and How to Diagnose Them

Symptom: Every COA line passes and a downstream lab, a competitor, or a regulator still finds a conversion solvent.
Root cause: The release panel copies the state’s minimum solvent list, which was written around butane, propane, and ethanol. Class 2 conversion solvents are not on it.
Diagnostic test: Ask your lab for the solvent list it actually calibrates for. If methylene chloride, toluene, chloroform, and hexane are not on it, the panel cannot see a conversion.
Fix: Specify the full USP 467 Class 1 and Class 2 list on every release lot. Headspace GC runs it in the same injection; the incremental cost is the standards, not the instrument time.

Symptom: Potency is on target, the product is labeled a named cultivar, and the terpene profile is nearly empty with CBD at 3 percent or more.
Root cause: Unreacted starting material in a converted oil. A Type I cultivar cannot produce a distillate with several percent CBD and no CBG or CBC.
Diagnostic test: Run the full cannabinoid panel with delta-8, delta-10, and iso-THC standards and compare the minor cannabinoid ratios to the cultivar’s flower COA.
Fix: Quarantine the lot, request the supplier’s input COA with a Class 2 solvent line, and treat any delta-10 or iso-THC detection as conclusive.

Symptom: Delta-8 reports at 1.5 to 4 percent in a delta-9 distillate and the lab calls it “normal degradation.”
Root cause: Delta-9 does isomerize to delta-8 under heat and acid, but a botanical distillate that was never acid-treated stays well under 1 percent. Percent-level delta-8 with a matching delta-10 peak is catalysis, not shelf age.
Diagnostic test: Check for delta-10 and the iso-THC isomers on the same chromatogram; degradation does not make those. Confirm delta-8 with a reference standard rather than a retention-time guess.
Fix: Escalate to GC-MS confirmation and a Class 2 solvent run before release.

Symptom: The supplier’s COA shows a clean solvent panel and the product still fails a Class 2 screen downstream.
Root cause: Reliance on an input COA that was scoped to the minimum list, or to a sample the supplier chose.
Diagnostic test: Compare the solvent list on the supplier COA against USP 467; a panel without methylene chloride and toluene lines is silent, not clean.
Fix: Retest incoming distillate at your own lab on the full list before it touches a cart. The license holder owns the result regardless of whose reactor produced it.

Symptom: A metals panel passes and the delta-9 distillate still shows the isomer spread of a Lewis acid route.
Root cause: The four-metal panel (arsenic, cadmium, lead, mercury) cannot see zinc or boron.
Diagnostic test: Add zinc to the ICP-MS run on any lot that fails the isomer screen; boron requires a dedicated method that most cannabis labs do not offer.
Fix: Use the isomer profile as the primary screen and metals as route confirmation, not the other way around.

A harder version of this problem arrives when the active ingredient has no reference standard at all. Material sold as EPN routinely reports as an unidentified peak, or gets left off the results table entirely, which is covered in our breakdown of how Euphorinol is made and why labs cannot name it. A non-detect from a panel that was never calibrated for the compound is not a finding.

A Release Protocol That Actually Catches Conversion

Run the full cannabinoid panel with delta-8, delta-10, exo-THC, and iso-THC standards on every distillate lot, and read the chromatogram, not just the table. Run residual solvents against the complete USP 467 Class 1 and Class 2 list, with methylene chloride, toluene, chloroform, and hexane calibrated and reported. Flag any lot with delta-8 above 1 percent, any quantifiable delta-10, iso-THC, or olivetol, any Class 2 solvent above its reporting limit, or a minor cannabinoid profile that does not match the claimed cultivar. Confirm flagged lots by GC-MS and, where the isomer spread points at a zinc route, by ICP-MS with zinc added. Keep the retained sample. A protocol like this costs a few hundred dollars per lot more than the state minimum and would have stopped the Colorado product at the first release.

This is the testing and compliance material we teach inside the extraction training program, where the COA reading module walks a real converted-distillate chromatogram against a botanical one: extractiontraining.com.

If you are a license holder, a lab, or a regulator trying to write this into a release specification, a supplier qualification program, or an enforcement method, that is consulting work we do: contact WKU Consulting.

Frequently Asked Questions

What is conversion oil?

THC distillate produced by isomerizing hemp CBD isolate with an acid catalyst rather than extracting it from THC-dominant cannabis. On a certificate it reads as 70 to 95 percent total THC with 1 to 15 percent delta-8, percent-level unreacted CBD, no CBG, CBC, THCV or CBN, and often a Class 2 solvent or a catalyst metal the state panel never screened. It loses federal hemp status on December 11, 2026 under Section 781 of Public Law 119-37, as a natural cannabinoid synthesized outside the plant.

Can chiral chromatography tell converted THC from plant THC?

Not when the feed was plant CBD. The ring closure that turns CBD into THC leaves the two stereocenters where the plant put them, so CBD-derived delta-9 is the same (6aR,10aR) enantiomer as botanical delta-9 and a chiral column sees one peak either way. Chiral analysis only exposes THC made by total synthesis with a racemic terpene. For conversion from CBD, look at delta-8 above 1 percent, delta-10 or iso-THC at any level, the missing minor cannabinoids, and the workup solvent.

Can a converted THC product pass a state compliance panel?

Yes, and that is the problem. Potency, the state’s minimum solvent list, pesticides, microbials, mycotoxins, and four heavy metals do not include the analytes that expose a conversion: Class 2 solvents like methylene chloride and toluene, delta-10 and iso-THC isomers, olivetol, and zinc.

What residual solvent proves THC was converted from CBD?

Methylene chloride is the clearest single flag because it has no use in extraction, flavoring, or formulation and is the standard workup solvent for the Lewis acid and mineral acid routes. Toluene and chloroform carry the same weight. Hexane and methanol are ambiguous on their own and decisive next to an isomer flag.

How much delta-8 is normal in a botanical delta-9 distillate?

Under 1 percent of total cannabinoids, and usually below the reporting limit. Percent-level delta-8 with delta-10 or iso-THC on the same chromatogram is catalysis, not shelf degradation.

What is hemp inversion?

Selling hemp-derived material, usually CBD isolate that has been chemically converted to THC, as if it were state-licensed cannabis. It is illegal in licensed markets because the licensed supply chain, the testing, and the tax stamp all assume the THC was grown, not synthesized.

What was found in the Colorado StayCon vapes?

Methylene chloride, detected by Bona Fides Laboratory in August 2026 during routine pesticide and mold screening. The manufacturer recalled 49 vape products in September 2026 and attributed the solvent to a botanically derived flavoring; Colorado bans both the conversion process and the solvent.

Which test should a buyer request before accepting a distillate lot?

A full USP 467 Class 1 and 2 residual solvent run plus a cannabinoid panel that resolves delta-8, delta-10, and iso-THC with reference standards. Together they cost a few hundred dollars and catch every route in the table above except a perfectly washed solid-resin conversion, which the residual CBD and missing minor cannabinoids still expose.

Why does a vape COA show non-detect delta-9 THC?

Because the panel only reports compounds it has a reference standard for. California’s rule names THC, THCA, CBD, CBDA, CBG, and CBN as the example panel, so a cart built on delta-8 THC-O acetate, HHC, or THCP elutes as an unnamed peak and delta-9 reads non-detect. Ask the lab for the chromatogram; any unidentified peak above 0.5 percent of area needs GC-MS before the product is called THC-free.

Can a lab detect THC-O acetate?

Yes, but not on a standard potency panel. GC-MS identifies it and the acetate survives a 290 C inlet without breaking down, LC-MS/MS handles CBD-di-O acetate, and DART-TOF confirms the exact mass. Certified standards were scarce enough that the first lab to report THC-O acetates in commercial products, in 2022, synthesized its own from THC and acetic anhydride.